APP下载

LMP2A调节EBV相关胃癌细胞中PD-L1的表达

2020-09-24吴烜童刚领程勃然余少康王树滨

中国实用医药 2020年24期

吴烜 童刚领 程勃然 余少康 王树滨

【摘要】 目的 探討膜潜伏蛋白2A(LMP2A)调节EB病毒(EBV)相关胃癌(EBVaGC)细胞中程序性死亡蛋白-配体1(PD-L1)的表达, 并分析LMP2A和PD-L1在胃癌细胞株中的表达及关系。方法 选取人胃癌细胞株SNU-719[EBV阳性(EBV+)]、AGS[EBV阴性(EBV-)], 采用实时荧光定量聚合酶链式反应 (qRT-PCR)方法检测胃癌细胞株SNU-719(EBV+)及AGS(EBV-)中LMP2A和PD-L1基因的表达水平, 佛波醇(TPA) 诱导SNU-719(EBV+)和AGS(EBV-)中LMP2A的表达后, 蛋白质印迹法(WB)检测LMP2A、PD-L1蛋白表达水平的变化。结果 PD-L1在EBV阳性细胞株SNU-719(EBV+)中的表达水平明显高于在AGS(EBV-)中的表达水平, 差异具有统计学意义(P<0.05)。SNU-719(EBV+)中LMP2A mRNA转录水平明显高于AGS(EBV-)细胞株, 差异具有统计学意义(P<0.05);AGS(EBV-)、SNU-719(EBV+)细胞株中PD-L1和LMP2A mRNA转录水平具有一致性。诱导12、24、48 h, LMP2A在SNU-719(EBV+)细胞株中表达呈上升趋势, 而AGS(EBV-)细胞株无变化。TPA诱导12 h后, SNU-719(EBV+)细胞PD-L1表达明显升高, 而AGS(EBV-)细胞株升高不明显。结论 EBV相关胃癌可能通过LMP2A介导的致癌途径上调PD-L1表达, 从而引起肿瘤免疫逃逸。这提示阻断LMP2A致癌途径和PD-1/PD-L1检查点抑制通路可为EBV感染的胃癌患者带来潜在临床益处。

【关键词】 EB病毒相关胃癌;膜潜伏蛋白2A;程序性死亡蛋白-配体1;免疫治疗

DOI:10.14163/j.cnki.11-5547/r.2020.24.087

【Abstract】 Objective   To discuss the expression of programmed death protein ligand 1 (PD-L1) in EB virus associated gastric cancer (EBVaGC) cells by latent membrane protein 2A (LMP2A), and analyze the expression and correlation between LMP2A and PD-L1. Methods   Human gastric cancer cell lines SNU-719 [EBV positive (EBV+)] and AGS [EBV negative (EBV-)] were selected. Quantitative real-time PCR (qRT-PCR) was used to detect the expression of LMP2A and PD-L1 in gastric cancer cell line SNU-719 (EBV+) and AGS (EBV-). Then the cells were induced with phorbol-12-tetradecanoate-13-acetate (TPA), Western blotting (WB) was used to detect the expression levels of LMP2A and PD-L1. Results   The expression level of PD-L1 in EBV positive cell line SNU-719 (EBV+) was significantly higher than that in AGS (EBV-), and the difference was statistically significant (P<0.05). The transcription level of LMP2A mRNA in SNU-719 (EBV+) was significantly higher than that in AGS (EBV-) cell lines, and the difference was statistically significant (P<0.05). The transcription levels of PD-L1 and LMP2A mRNA in AGS (EBV-) and SNU-719 (EBV+) cell lines were consistent. At 12, 24, and 48 h after induction, the expression of LMP2A in SNU-719 (EBV+) cell line showed an upward trend, while the expression of AGS (EBV-) cell line remained unchanged. After 12 h of TPA induction, the expression of PD-L1 in SNU-719 (EBV+) cells was significantly increased, while that of AGS (EBV-) cell lines was not significantly increased. Conclusion   EBV associated gastric cancer may upregulate the expression of PD-L1 through LMP2A-mediated carcinogenic pathway, resulting in tumor immune escape. These findings indicated that simultaneous inhibition of PD-1/PD-L1 and LMP2A may provide potential survival benefits to patients with EBV associated gastric cancer.

【Key words】 EB virus associated gastric cancer; Latent membrane protein 2A; Programmed death protein ligand 1; Immunotherapy

胃癌是世界范围内最常见的恶性肿瘤之一。在我国, 胃癌的发病率和病死率居高不下, 位居我国恶性肿瘤发病率为第2位, 死亡率位居第3位, 发患者数及死亡人数均占全球胃癌发病总例数的50%左右[1, 2]。尽管早期胃癌的治疗预后较好, 5年无病生存达70%以上, 然而临床Ⅲ~Ⅳ期患者在综合治疗后仍容易复发和转移, 复发、转移性胃癌中位生存时间只有9~10个月[3]。除了20%的胃癌患者具有人表皮生长因子受体-2(HER-2)扩增可以应用靶向治疗外, 其他类型的胃癌目前尚缺少明确有效的靶向药物, 临床急需探索新的高效、低毒的药物。2014年, 癌症基因组图谱计划的研究者将胃癌分为4种基因亚型[4], 其中一类亚型为EB病毒(epstein-barr virus, EBV)阳性胃癌也称EBVaGC, 根据既往研究报道, 全球范围内EBVaGC发病率为3.3%~26.3%, 其中以东亚占比最多[5]。最近研究发现EBVaGC有一个非常明显的病理特征:癌细胞周围浸润了大量的淋巴细胞, 但是并不能识别及清除癌细胞, 呈现典型的肿瘤免疫逃逸状态[6]。……

登录APP查看全文